Mylan ROE 2006-2020 | MYL

Current and historical return on equity (ROE) values for Mylan (MYL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Mylan ROE for the three months ending March 31, 2020 was 20.00%.
Mylan ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2020-03-31 $0.06B $11.26B 0.54%
2019-12-31 $0.02B $11.88B 0.14%
2019-09-30 $0.05B $11.46B 0.40%
2019-06-30 $0.03B $11.90B 0.28%
2019-03-31 $0.24B $11.89B 1.99%
2018-12-31 $0.35B $12.17B 2.85%
2018-09-30 $0.55B $12.07B 4.30%
2018-06-30 $0.46B $12.21B 3.52%
2018-03-31 $0.72B $13.18B 5.44%
2017-12-31 $0.70B $13.31B 5.44%
2017-09-30 $0.87B $13.29B 7.11%
2017-06-30 $0.66B $12.83B 5.57%
2017-03-31 $0.53B $11.66B 4.74%
2016-12-31 $0.48B $11.12B 4.41%
2016-09-30 $0.26B $11.83B 2.44%
2016-06-30 $0.81B $10.33B 8.02%
2016-03-31 $0.81B $10.28B 8.18%
2015-12-31 $0.85B $9.77B 8.88%
2015-09-30 $0.84B $9.82B 10.62%
2015-06-30 $0.91B $9.57B 14.41%
2015-03-31 $0.87B $9.09B 18.19%
2014-12-31 $0.93B $3.28B 28.09%
2014-09-30 $0.92B $3.41B 28.50%
2014-06-30 $0.58B $3.35B 18.21%
2014-03-31 $0.63B $3.19B 20.54%
2013-12-31 $0.62B $2.96B 20.76%
2013-09-30 $0.61B $3.23B 19.52%
2013-06-30 $0.66B $2.95B 20.54%
2013-03-31 $0.62B $2.89B 18.95%
2012-12-31 $0.64B $3.36B 18.37%
2012-09-30 $0.61B $3.62B 17.24%
2012-06-30 $0.55B $3.20B 15.85%
2012-03-31 $0.56B $3.78B 15.31%
2011-12-31 $0.54B $3.51B 14.49%
2011-09-30 $0.41B $3.49B 11.00%
2011-06-30 $0.36B $3.88B 9.65%
2011-03-31 $0.27B $3.92B 7.57%
2010-12-31 $0.22B $3.62B 6.70%
2010-09-30 $0.22B $3.54B 6.98%
2010-06-30 $0.08B $2.98B 2.46%
2010-03-31 $0.08B $3.18B 2.70%
2009-12-31 $0.09B $3.15B 3.16%
2009-09-30 $0.03B $3.07B 1.19%
2009-06-30 $0.26B $2.91B 9.04%
2009-03-31 $0.18B $2.65B 6.31%
2008-12-31 $-0.34B $2.79B -11.15%
2008-09-30 $-1.60B $2.98B -50.65%
2008-06-30 $-1.64B $3.13B -56.53%
2008-03-31 $-1.54B $3.16B -60.56%
2007-12-31 $-1.16B $3.40B -53.74%
2007-09-30 $0.29B $1.89B 18.48%
2007-06-30 $0.22B $1.73B 16.34%
2007-03-31 $0.22B $1.65B 19.04%
2006-09-30 $0.20B $0.96B 23.94%
2006-06-30 $0.16B $0.87B 19.70%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $8.824B $11.501B
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $13.685B 5.07
Dr Reddy's Laboratories (RDY) India $8.856B 21.21
Bausch Health Cos (BHC) Canada $6.557B 4.34
ASPEN PHARMACR (APNHY) South Africa $3.574B 0.00
BridgeBio Pharma (BBIO) United States $3.560B 0.00
Supernus Pharmaceuticals (SUPN) United States $1.267B 11.12
Amphastar Pharmaceuticals (AMPH) United States $0.861B 44.38
Homology Medicines (FIXX) United States $0.644B 0.00
Assembly Biosciences (ASMB) United States $0.638B 0.00
Voyager Therapeutics (VYGR) United States $0.450B 0.00
Personalis (PSNL) United States $0.375B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.368B 0.00
CymaBay Therapeutics (CBAY) United States $0.255B 0.00
Mallinckrodt Public Limited Company (MNK) United Kingdom $0.238B 0.33
Sol-Gel Technologies (SLGL) Israel $0.157B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.131B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.078B 0.00
Teligent (TLGT) United States $0.021B 0.00
China Pharma Holdings (CPHI) China $0.020B 0.00
Akorn (AKRX) United States $0.012B 0.64